{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T06:44:23Z","timestamp":1776062663527,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is an autoimmune disease. Recently, the prevalence of very late-onset MG (VLOMG; onset \u2265 65 years) has rapidly increased. The treatment of VLOMG groups is associated with several challenges, including multiple comorbidities, polypharmacy, and immunosenescence. Efgartigimod, which is the first approved neonatal Fc receptor (FcRN) antagonist, is reported to rapidly ameliorate MG symptoms with a favorable safety profile. Thus, efgartigimod is a potential novel therapeutic for VLOMG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study retrospectively analyzed the clinical data of patients with VLOMG treated with efgartigimod at our center over the past two years to assess its long-term efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study retrospectively enrolled 62 patients with VLOMG who received at least one efgartigimod treatment cycle. The primary efficacy outcomes were the proportion of patients achieving minimum symptom expression (MSE) and the reduction in glucocorticoid dosage. The secondary efficacy outcomes were changes in Myasthenia Gravis-Activities of Daily Living (MG-ADL) scale scores, Quantitative Myasthenia Gravis (QMG) scale scores, Myasthenia Gravis Quality of Life 15-item revised (MG-QoL15r) scale scores, and scores of key muscle groups (ocular, bulbar, respiratory, axial, and limb muscles) relative to baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study enrolled 62 eligible patients with VLOMG. Of these 62 patients, 37, 10, and 15 completed 1, 2, and \u22653 treatment cycles, respectively. The cumulative MSE achievement rate was 41.9% (26\/62) by the end of the study. MG-ADL, QMG and MG-QoL15r scores after treatment were significantly reduced relatively to baseline in patients who underwent 1, 2, and \u2265 3 treatment cycles (all P &amp;lt; 0.001, P &amp;lt; 0.01, and P &amp;lt; 0.05, respectively). Subgroup analysis of muscle groups revealed that bulbar, limb (including axial), and ocular muscle function after treatment was significantly improved relatively to baseline in 37 patients (all P &amp;lt; 0.01). Limb (including axial) muscle function after treatment was significantly improved relatively to baseline in 15 patients (P &amp;lt; 0.05). Glucocorticoid dosage after treatment was significantly decreased relatively to baseline in patients who underwent 1, 2, and \u2265 3 treatment cycles (P &amp;lt; 0.0001, P &amp;lt; 0.05, P &amp;lt; 0.05, respectively). During treatment with efgartigimod, one patient developed an allergic rash, one patient experienced gastric discomfort, and two patients reported headache.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrated that efgartigimod effectively ameliorates symptoms and improves the quality of life in patients with VLOMG and enables short-term glucocorticoid dosage reduction. Thus, efgartigimod seems to be a safe and effective long-term therapeutic agent for VLOMG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1808357","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:45:45Z","timestamp":1776059145000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of efgartigimod in very-late-onset myasthenia gravis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yunbin","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Qingdao University","place":["Qingdao, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meijie","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Qingdao University","place":["Qingdao, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Rong","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Qingdao University","place":["Qingdao, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xupeng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Qingdao University","place":["Qingdao, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Qingdao University","place":["Qingdao, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Qingdao University","place":["Qingdao, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaona","family":"Sui","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Qingdao University","place":["Qingdao, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e976","DOI":"10.1212\/wnl.0000000000012463","article-title":"Characterization of LRP4\/Agrin antibodies from a patient with myasthenia gravis","volume":"97","author":"Yu","year":"2021","journal-title":"Neurology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines11020449","article-title":"Immunological and structural characterization of titin main immunogenic region; I110 domain is the target of titin antibodies in myasthenia gravis","volume":"11","author":"Stergiou","year":"2023","journal-title":"Biomedicines"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0739-22","article-title":"Anti-Kv1.4 antibody-positive nivolumab-induced myasthenia gravis and myositis presenting with bilateral ptosis and demonstrating different pathophysiologies","volume":"62","author":"Kitazaki","year":"2023","journal-title":"Intern Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines11030732","article-title":"Muscle and muscle-like autoantigen expression in myasthenia gravis thymus: Possible molecular hint for autosensitization","volume":"11","author":"Iacomino","year":"2023","journal-title":"Biomedicines"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/cells14100739","article-title":"The role of complement in the pathogenesis and treatment of myasthenia gravis","volume":"14","author":"Martinez Salazar","year":"2025","journal-title":"Cells"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207863","article-title":"Hospitalizations and mortality from myasthenia gravis: Trends from 2 US national datasets","volume":"102","author":"Habib","year":"2024","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000539577","article-title":"Prevalence, incidence, and mortality of myasthenia gravis and myasthenic syndromes: A systematic review","volume":"59","author":"Sciancalepore","year":"2024","journal-title":"Neuroepidemiology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42466-020-00091-z","article-title":"Outcome measures and treatment effectiveness in late onset myasthenia gravis","volume":"2","author":"Pasqualin","year":"2020","journal-title":"Neurol Res Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.heliyon.2024.e28893","article-title":"Clinical characteristics of late-onset myasthenia gravis","volume":"10","author":"Sun","year":"2024","journal-title":"Heliyon"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1,8","DOI":"10.1016\/j.jns.2024.123314","article-title":"Aging and infectious diseases in myasthenia gravis","volume":"468","author":"Bril","year":"2025","journal-title":"J Neurol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07368-0","article-title":"Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients","volume":"45","author":"Di Stefano","year":"2024","journal-title":"Neurological Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/jci97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2025.06.012","article-title":"Effect of intravenous immunoglobulin or plasmapheresis in myasthenic crisis and worsening myasthenia gravis compared to without rescue treatment","volume":"47","author":"Kalita","year":"2025","journal-title":"Clin Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: A multicenter real\u2010world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5,9","DOI":"10.1177\/17562864251319656","article-title":"Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes","volume":"18","author":"Jin","year":"2025","journal-title":"Ther Adv Neurological Disord"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1579859","article-title":"Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG\u2010ADL in myasthenia gravis clinical research and care","volume":"65","author":"Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318217e735","article-title":"Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada","volume":"76","author":"Pakzad","year":"2011","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2023.02.013","article-title":"Clinical characteristics and prognosis of very late-onset myasthenia gravis in China","volume":"33","author":"Tang","year":"2023","journal-title":"Neuromuscular Disord"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334086","article-title":"Efgartigimod efficacy and safety in refractory myasthenia gravis: UK\u2019s first real-world experience","volume":"96","author":"Moniz Dion\u00edsio","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00748-4","article-title":"Real-world experience with FcRn inhibitors efgartigimod and rozanolixizumab in myasthenia gravis: Administration in multiple cycles and transition from intravenous to subcutaneous formulation","volume":"14","author":"Yoshikawa","year":"2025","journal-title":"Neurol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02448-4","article-title":"Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients","volume":"19","author":"Nelke","year":"2022","journal-title":"J Neuroinflamm"},{"key":"B26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ene.12599","article-title":"Myasthenia gravis and risks for comorbidity","volume":"22","author":"Gilhus","year":"2014","journal-title":"Eur J Neurol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","article-title":"Metabolic regulation of T cell longevity and function in tumor immunotherapy","volume":"26","author":"Kishton","year":"2017","journal-title":"Cell Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.immuni.2019.10.009","article-title":"CD4+ T cell help is required for the formation of a cytolytic CD8+ T cell subset that protects against chronic infection and cancer","volume":"51","author":"Zander","year":"2019","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.123.318974","article-title":"Single-cell transcriptomics reveals crucial cell subsets and functional heterogeneity associated with carotid atherosclerosis and cerebrovascular events","volume":"43","author":"Tan","year":"2023","journal-title":"Arteriosclerosis Thrombosis Vasc Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7,9","DOI":"10.1186\/s12883-022-02692-4","article-title":"A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis","volume":"22","author":"Harris","year":"2022","journal-title":"BMC Neurol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05751-1","article-title":"Efficacy and safety of immunosuppressants and monoclonal antibodies in adults with myasthenia gravis: a systematic review and network meta-analysis","volume":"22","author":"Gu","year":"2024","journal-title":"J Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1808357\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:45:46Z","timestamp":1776059146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1808357\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1808357"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1808357","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1808357"}}